606 related articles for article (PubMed ID: 26977787)
1. Amorphous Formulation and in Vitro Performance Testing of Instantly Disintegrating Buccal Tablets for the Emergency Delivery of Naloxone.
Alqurshi A; Kumar Z; McDonald R; Strang J; Buanz A; Ahmed S; Allen E; Cameron P; Rickard JA; Sandhu V; Holt C; Stansfield R; Taylor D; Forbes B; Royall PG
Mol Pharm; 2016 May; 13(5):1688-98. PubMed ID: 26977787
[TBL] [Abstract][Full Text] [Related]
2. The preparation of rapidly disintegrating tablets in the mouth.
Sugimoto M; Matsubara K; Koida Y; Kobayashi M
Pharm Dev Technol; 2001 Nov; 6(4):487-93. PubMed ID: 11775950
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Mannitol Hemihydrate on the Secondary Drying Dynamics of a Protein Formulation: A Case Study.
Srinivasan JM; Wegiel LA; Hardwick LM; Nail SL
J Pharm Sci; 2017 Dec; 106(12):3583-3590. PubMed ID: 28867201
[TBL] [Abstract][Full Text] [Related]
4. Development of manufacturing method for rapidly disintegrating oral tablets using the crystalline transition of amorphous sucrose.
Sugimoto M; Narisawa S; Matsubara K; Yoshino H; Nakano M; Handa T
Int J Pharm; 2006 Aug; 320(1-2):71-8. PubMed ID: 16750604
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.
Sawicki E; Schellens JH; Beijnen JH; Nuijen B
Drug Dev Ind Pharm; 2017 Apr; 43(4):584-594. PubMed ID: 28010129
[TBL] [Abstract][Full Text] [Related]
6. Development and optimization of lyophilized orally disintegrating tablets using factorial design.
Ahmed IS; Shamma RN; Shoukri RA
Pharm Dev Technol; 2013; 18(4):935-43. PubMed ID: 22107175
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of swelling induced-orally disintegrating tablets by microwave irradiation.
Sano S; Iwao Y; Kimura S; Itai S
Int J Pharm; 2011 Sep; 416(1):252-9. PubMed ID: 21763765
[TBL] [Abstract][Full Text] [Related]
8. Freeze drying: exploring potential in development of orodispersible tablets of sumatriptan succinate.
Gugulothu D; Desai P; Pandharipande P; Patravale V
Drug Dev Ind Pharm; 2015 Mar; 41(3):398-405. PubMed ID: 24384027
[TBL] [Abstract][Full Text] [Related]
9. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
10. Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride.
Stange U; Führling C; Gieseler H
J Pharm Sci; 2014 Apr; 103(4):1233-45. PubMed ID: 24532095
[TBL] [Abstract][Full Text] [Related]
11. Co-crystallization for enhanced dissolution rate of bicalutamide: preparation and evaluation of rapidly disintegrating tablets.
Essa EA; Elbasuony AR; Abdelaziz AE; El Maghraby GM
Drug Dev Ind Pharm; 2019 Aug; 45(8):1215-1223. PubMed ID: 30661420
[No Abstract] [Full Text] [Related]
12. Influence of non-water-soluble placebo pellets of different sizes on the characteristics of orally disintegrating tablets manufactured by freeze-drying.
Stange U; Führling C; Gieseler H
J Pharm Sci; 2013 Jun; 102(6):1786-1799. PubMed ID: 23568590
[TBL] [Abstract][Full Text] [Related]
13. Development of a multiparticulate drug delivery system for in situ amorphisation.
Holm TP; Kokott M; Knopp MM; Boyd BJ; Berthelsen R; Quodbach J; Löbmann K
Eur J Pharm Biopharm; 2022 Nov; 180():170-180. PubMed ID: 36191869
[TBL] [Abstract][Full Text] [Related]
14. Effect of formulated ingredients on rapidly disintegrating oral tablets prepared by the crystalline transition method.
Sugimoto M; Narisawa S; Matsubara K; Yoshino H; Nakano M; Handa T
Chem Pharm Bull (Tokyo); 2006 Feb; 54(2):175-80. PubMed ID: 16462059
[TBL] [Abstract][Full Text] [Related]
15. A pragmatic approach for engineering porous mannitol and mechanistic evaluation of particle performance.
Al-Khattawi A; Koner J; Rue P; Kirby D; Perrie Y; Rajabi-Siahboomi A; Mohammed AR
Eur J Pharm Biopharm; 2015 Aug; 94():1-10. PubMed ID: 25960332
[TBL] [Abstract][Full Text] [Related]
16. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets.
Chandrasekhar R; Hassan Z; Alhusban F; Smith AM; Mohammed AR
Eur J Pharm Biopharm; 2009 May; 72(1):119-29. PubMed ID: 19073253
[TBL] [Abstract][Full Text] [Related]
17. Effects of Excipient Interactions on the State of the Freeze-Concentrate and Protein Stability.
Jena S; Horn J; Suryanarayanan R; Friess W; Aksan A
Pharm Res; 2017 Feb; 34(2):462-478. PubMed ID: 27981449
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
[TBL] [Abstract][Full Text] [Related]
19. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
20. A new formulation for orally disintegrating tablets using a suspension spray-coating method.
Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
Int J Pharm; 2009 Dec; 382(1-2):80-7. PubMed ID: 19686825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
